The Effect of Cinnamon on Glucose Control and Lipid Parameters

William L Baker, Pharm.D., BCPS;¹,² Gabriela Gutierrez-Williams, Pharm.D.;² C. Michael White, Pharm.D., FCP, FCCP;¹,² Jeffrey Kluger, MD;³ Craig I Coleman, Pharm.D.¹,²

University of Connecticut¹, Storrs, CT and Drug Information² and Cardiology³ at Hartford Hospital, Hartford, CT

Running title: Cinnamon in Diabetes Mellitus

Corresponding Author: Craig I. Coleman, Pharm.D.
Assistant Professor of Pharmacy Practice
University of Connecticut
Hartford Hospital
80 Seymour Street
Hartford, CT 06102-5037
ccolema@harthosp.org

Received for publication 29 August 2007 and accepted in revised form 28 September 2007.
ABSTRACT:

**Objective** – To perform a meta-analysis of randomized controlled trials of cinnamon to better characterize its impact on glucose and plasma lipids.

**Research Design & Methods** – A systematic literature search through July 2007 was conducted to identify randomized, placebo-controlled trials of cinnamon that reported data on hemoglobin A1c (HbA1c), fasting blood glucose (FBG) or lipid parameters. The mean change in each study endpoint from baseline was treated as a continuous variable and the weighted mean difference was calculated as the difference between the mean value in the treatment and control groups. A random-effects model was used.

**Results** – Five prospective, randomized controlled trials (n=282) were identified. Upon meta-analysis, the use of cinnamon did not significantly alter HbA1c, FBG, or lipid parameters. Subgroup and sensitivity analyses did not significantly change the results.

**Conclusion** – Cinnamon does not appear to improve HbA1c, FBG or lipid parameters in patients with type 1 or 2 DM.
INTRODUCTION:
Cinnamon contains biologically active substances that have demonstrated insulin-mimetic properties. *In vitro* (1,2) and *in vivo* (3,4) studies have shown that cinnamon enhances glucose uptake by activating insulin receptor kinase activity, autophosphorylation of the insulin receptor, and glycogen synthase activity. Other recent studies have demonstrated the ability of cinnamon to reduce lipid levels in fructose-fed rats, potentially via inhibiting hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity. (5,6)

Several clinical trials (7-11) have investigated the impact of cinnamon on glucose and plasma lipid concentrations in patients with diabetes mellitus (DM) but yielded conflicting results and had modest sample sizes. Therefore, we performed a meta-analysis of randomized controlled trials of cinnamon to better characterize its impact on glucose and plasma lipids.

RESEARCH DESIGN & METHODS:
To be included in this meta-analysis, trials had to be randomized, placebo-controlled trials of cinnamon and report data on hemoglobin A1c (HbA1c), fasting blood glucose (FBG) or lipid parameters.

Using the above-mentioned inclusion criteria, we conducted a systematic literature search of MEDLINE, CINAHL, Web of Science and the Cochrane Library from the earliest possible date through July 2007. We used the following Medical Subject Headings (MeSH) and keywords: “cinnamomum”, “cinnamomum cassia”, “cinnamomum zeylanicum”, “cinnamomum aromaticum” in combination with “diabetes mellitus”. Results were limited to clinical trials in humans. A manual search of retrieved articles was also performed. Three investigators independently reviewed potentially relevant articles and abstracted necessary data.

The mean change in each study endpoint from baseline was treated as a continuous variable and the weighted mean difference (WMD) was calculated as the difference between the mean value in the treatment and control groups. Advanced statistical methods were used to impute change scores as suggested by Follmann and colleagues (12,13) We conducted subgroup and sensitivity analyses to assess whether DM type had an effect on our results. A random-effects model was used to calculate WMD and 95% confidence intervals. Statistical heterogeneity was addressed using the $I^2$ statistic. Visual inspection of funnel plots was used to assess for publication bias. The funnel plot is a pictorial representation of each study plotted by its effect size on the horizontal axis and variance on the vertical axis. If the plot represents an inverted symmetrical funnel, it is said that publication bias is unlikely. Statistics were performed using StatsDirect, version 2.4.6.
RESULTS:
The initial search yielded 24 potential literature citations. Of those, fourteen citations were human studies, and only six were clinical trials. Furthermore, one citation was excluded from the analysis since it was not a trial of cinnamon. Thus, a total of 5 clinical trials (n=282 subjects, follow-up range 5.7-16.0 weeks) were included in the meta-analysis.(7-11) All of the studies used *cinnamomum cassia* and doses ranged from one to 6 grams. Four provided powder-filled capsules,(7,8,9,11), while one provided aqueous-filled capsules.(10) Four of the studies dosed cinnamon during meals.(8-11) The study by Khan and colleagues looked at 3 different doses of cinnamon and these results were combined in this meta-analysis, since no dose-response relationship was found with cinnamon over this dosage range.(9) Studies were in type 2 DM (8-11) or adolescents with type 1 DM.(7) Studies were conducted in the United States (7,8), Europe (10,11), and Pakistan.(9) Patient withdrawals were appropriately reported in all studies.

Upon meta-analysis, the use of cinnamon did not significantly alter HbA1c, FBG or lipid parameters.(Table 1) No statistical heterogeneity was observed for the HbA1c or HDL analyses ($I^2=0\%$). Each of the other analysis displayed a high degree of statistical heterogeneity ($I^2>79.6\%$ for all). Visual inspection of funnel plots (not shown) could not rule out publication bias for any analysis.

After conducting subgroup and sensitivity analyses, the exclusion of non-blinded trials (9) or evaluating type 1 (7) and type 2 diabetics (8-11) separately did not significantly change our meta-analysis’ results. Little to no statistical heterogeneity was observed for any of these subsequent analyses.

CONCLUSIONS:
In this meta-analysis of 5 randomized, placebo-controlled trials, patients with type 1 or 2 DM receiving cinnamon did not demonstrate statistically or clinically significant changes in HbA1c, FBG or lipid parameters as compared to patients receiving placebo.

The median duration of patient treatment and follow-up in all included trials was 12 weeks. These durations of treatment are appropriate to observe clinically significant changes in FBG and lipids.(14-16) However, they are likely too short to see the full effect of treatment on HbA1c.(14) We would still have expected a trend or tendency towards beneficial changes in HbA1c with cinnamon supplementation compared to placebo after this shorter time period, if in fact such a benefit truly existed. Instead, HbA1c levels increased to a greater extent with cinnamon than with placebo in our meta-analysis, thus reducing our confidence in cinnamon’s impact on long term glycemic control.
There are some additional limitations to this meta-analysis that should be noted. First, we identified only a small number of eligible studies. Thus, our meta-analysis may be underpowered to detect statistically significant differences in many of the endpoints. Post-hoc sample size calculations suggest that if the differences were due to a real effect rather than chance that 1,166-6,853 patients would be needed. Even if the observed beneficial changes observed in some of endpoints were found to be statistically significant, their clinical significance could still be debated. We cannot determine the reason for differences between the Khan study and the others. Ethnicity or cultural dietary differences, dose, lack of verification of double-blinding, or chance resulting from small sample size in the Khan study could explain the disparate findings. In 4 of the 5 studies, including Khan, they did not mention if the aroma associated with cinnamon and placebo were similar which could have affected the adequacy of double-blinding. Finally, as with any meta-analysis, the potential for publication bias is of concern. Visual inspection of our meta-analysis’ funnel plot could not rule out publication bias.

Cinnamon does not appear to improve HbA1c, FBG or lipid parameters in patients with type 1 or 2 DM. Cinnamon’s ability to prevent diabetes in patients with pre-diabetes and those at high-risk is unknown.
REFERENCES:


Table 1. Results of Meta-analysis of Randomized Controlled Trials Evaluating Cinnamon*

<table>
<thead>
<tr>
<th></th>
<th>HbA1c</th>
<th>FBG</th>
<th>TC</th>
<th>TG</th>
<th>HDL-C</th>
<th>LDL-C</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Base-Case</strong></td>
<td>0.07</td>
<td>-17.15</td>
<td>-9.63</td>
<td>-28.44</td>
<td>1.58</td>
<td>-4.71</td>
</tr>
<tr>
<td></td>
<td>(-0.11 to 0.26)</td>
<td>(-47.58 to 13.27)</td>
<td>(-35.94 to 16.67)</td>
<td>(-61.81 to 4.94)</td>
<td>(-0.74 to 3.89)</td>
<td>(-18.12 to 8.71)</td>
</tr>
<tr>
<td></td>
<td>n=4 (204)</td>
<td>n=4 (207)</td>
<td>n=4 (207)</td>
<td>n=4 (207)</td>
<td>n=3 (147)</td>
<td>n=4 (207)</td>
</tr>
<tr>
<td><strong>Type 1 DM only</strong></td>
<td>0.3</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>(-0.01 to 0.70)</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>n=1 (57)</td>
<td>n=1 (57)</td>
<td>n=1 (57)</td>
<td>n=1 (57)</td>
<td>n=1 (57)</td>
<td>n=1 (57)</td>
</tr>
<tr>
<td><strong>Type 2 DM only</strong></td>
<td>0.01</td>
<td>-17.15</td>
<td>-9.63</td>
<td>-28.44</td>
<td>1.58</td>
<td>-4.71</td>
</tr>
<tr>
<td></td>
<td>(-0.20 to 0.22)</td>
<td>(-47.58 to 13.27)</td>
<td>(-35.94 to 16.67)</td>
<td>(-61.81 to 4.94)</td>
<td>(-0.74 to 3.89)</td>
<td>(-18.12 to 8.71)</td>
</tr>
<tr>
<td></td>
<td>n=3 (147)</td>
<td>n=4 (207)</td>
<td>n=4 (207)</td>
<td>n=4 (207)</td>
<td>n=3 (147)</td>
<td>n=4 (207)</td>
</tr>
</tbody>
</table>

* All results are reported in mg/dL as weighted mean differences with 95% confidence intervals using a random-effects model

DM = diabetes mellitus; FBG = fasting blood glucose; HbA1c = hemoglobin A1c; HDL-C = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol; n = number of studies; N/A = not applicable; TC = total cholesterol; TG = triglycerides